Literature DB >> 25120011

Reproductive health and endocrine disruption in women with breast cancer: a pilot study.

Ashlesha Patel1, Alicia Roston, Almae Uy, Erika Radeke, Arden Roston, Louis Keith, H A Zaren.   

Abstract

PURPOSE: The purpose of this study was to assess whether incorporation of an original reproductive health assessment and algorithm into breast cancer care helps providers appropriately manage patient reproductive health goals and to follow laboratory markers for fertility and correlate these with menstruation.
METHODS: This prospective observational pilot study was set in an urban, public hospital. Newly diagnosed premenopausal breast cancer patients between 18 and 49 years old were recruited for this study prior to chemotherapy initiation. As the intervention, these patients received a reproductive health assessment and care per the study algorithm at 3-month intervals for 24 months. Blood samples were also collected at the same time intervals. The main outcome measures were to assess if the reproductive health management was consistent with patient goals and to track any follicle-stimulating hormone (FSH) and thyroid-stimulating hormone (TSH) level changes throughout treatment and post-treatment period.
RESULTS: Two patients were pregnant at study initiation. They received obstetric consultations, opted to continue pregnancies, and postpone treatment; both delivered at term without complications. One woman desired future childbearing and received fertility preservation counseling. All women received family planning consultations and received/continued effective contraceptive methods. Seventy-three percent used long-term contraception, 18 % remained abstinent, and 9 % used condoms. During chemotherapy, FSH rose to menopausal levels in 82 % of patients and TSH rose significantly in 9 %. While 82 % of women experienced amenorrhea, 44 % of these women resumed menstruation after chemotherapy.
CONCLUSIONS: The assessment and algorithm were useful in managing patients' reproductive health needs. Chemotherapy-induced endocrine disruption impacted reproductive health.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25120011     DOI: 10.1007/s00520-014-2381-2

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  27 in total

1.  Anti-Müllerian hormone (AMH) defines, independent of age, low versus good live-birth chances in women with severely diminished ovarian reserve.

Authors:  Norbert Gleicher; Andrea Weghofer; David H Barad
Journal:  Fertil Steril       Date:  2010-06-11       Impact factor: 7.329

2.  Communicating contraceptive effectiveness: an updated counseling chart.

Authors:  Markus J Steiner; James Trussell; Sarah Johnson
Journal:  Am J Obstet Gynecol       Date:  2007-07       Impact factor: 8.661

3.  Unintended pregnancy and postpartum contraceptive use in women with and without chronic medical disease who experienced a live birth.

Authors:  Julie Chor; Kristin Rankin; Bryna Harwood; Arden Handler
Journal:  Contraception       Date:  2011-01-20       Impact factor: 3.375

4.  Reproduction rates after cancer treatment: experience from the Norwegian radium hospital.

Authors:  Milada Cvancarova; Sven Ove Samuelsen; Henriette Magelssen; Sophie Dorothea Fosså
Journal:  J Clin Oncol       Date:  2008-12-15       Impact factor: 44.544

Review 5.  The effect of cytotoxic chemotherapy on female fertility.

Authors:  Sharon Chasle; Christine C How
Journal:  Eur J Oncol Nurs       Date:  2003-06       Impact factor: 2.398

6.  Effects of treatment on fertility in long-term survivors of childhood or adolescent cancer.

Authors:  J Byrne; J J Mulvihill; M H Myers; R R Connelly; M D Naughton; M R Krauss; S C Steinhorn; D D Hassinger; D F Austin; K Bragg
Journal:  N Engl J Med       Date:  1987-11-19       Impact factor: 91.245

Review 7.  Management of reproductive needs in cancer patients: clinical perspectives.

Authors:  Mohamed F Mitwally
Journal:  Expert Rev Anticancer Ther       Date:  2008-10       Impact factor: 4.512

8.  Antimullerian hormone and inhibin B are hormone measures of ovarian function in late reproductive-aged breast cancer survivors.

Authors:  H Irene Su; Mary D Sammel; Jamie Green; Luke Velders; Corrie Stankiewicz; Jennifer Matro; Ellen W Freeman; Clarisa R Gracia; Angela DeMichele
Journal:  Cancer       Date:  2010-02-01       Impact factor: 6.860

9.  Breast cancer, pregnancy, and breastfeeding.

Authors:  Michael Helewa; Pierre Lévesque; Diane Provencher; Robert H Lea; Vera Rosolowich; Heather M Shapiro
Journal:  J Obstet Gynaecol Can       Date:  2002-02

10.  Reproductive health issues in women with cancer.

Authors:  Ashlesha A Patel; Sreedevi Mini; Rachana P Sutaria; Monique Brown Schoenhage; Ashok R Patel; Erika K Radeke; Howard A Zaren
Journal:  J Oncol Pract       Date:  2008-03       Impact factor: 3.840

View more
  3 in total

Review 1.  Unintended Pregnancy: A Systematic Review of Contraception Use and Counseling in Women With Cancer.

Authors:  Laura Britton
Journal:  Clin J Oncol Nurs       Date:  2017-04-01       Impact factor: 1.027

2.  Occurrence and recall rates of fertility discussions with young breast cancer patients.

Authors:  Rahul Banerjee; Ekaterini Tsiapali
Journal:  Support Care Cancer       Date:  2015-05-13       Impact factor: 3.603

3.  The association between CCR5 Δ32 polymorphism and susceptibility to breast cancer.

Authors:  Junlong Li; Yuan Peng; Hui Liu; Qiang Wu
Journal:  Oncotarget       Date:  2017-08-05
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.